menu
    • menu
    [{"orgOrder":0,"company":"Philochem","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Radiolabeled Compounds","year":"2025","type":"Licensing Agreement","leadProduct":"68-Ga OncoACP3","moa":"||ACP3","graph1":"Oncology","graph2":"Phase I","graph3":"Philochem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Philochem \/ RayzeBio","highestDevelopmentStatusID":"6","companyTruncated":"Philochem \/ RayzeBio"},{"orgOrder":0,"company":"Philochem","sponsor":"Isotopia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"177-Lu OncoFAP-23","moa":"||FAP","graph1":"Oncology","graph2":"Preclinical","graph3":"Philochem","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Philochem \/ Philochem","highestDevelopmentStatusID":"4","companyTruncated":"Philochem \/ Philochem"}]

    Find Clinical Drug Pipeline Developments & Deals by Philochem

    Menu

    Philochem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Philochem

                            Switzerland arrow
                            EPSC
                            Not Confirmed

                            Philochem

                            Switzerland arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 68-Ga OncoACP3,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : RayzeBio

                            Deal Size : $1,350.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3 to RayzeBio

                            Details : Under the licensing agreement, RayzeBio will hold the rights to develop, manufacture, and commercialise 68-Ga OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : $350.0 million

                            June 10, 2025

                            Lead Product(s) : 68-Ga OncoACP3,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : RayzeBio

                            Deal Size : $1,350.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Philochem

                            Switzerland arrow
                            EPSC
                            Not Confirmed

                            Philochem

                            Switzerland arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu OncoFAP-23,Inapplicable

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Isotopia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Philochem AG, Seibersdorf Labor GmbH and Isotopia Announce Supply, Development, And Manufacturing Agreements

                            Details : 177Lu-OncoFAP-23 exhibits, in pre-clinical models, a very high and selective tumor uptake and with a significantly extended residence time at the site of disease, compared to other 177Lu-FAP-ligands.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 13, 2022

                            Lead Product(s) : 177-Lu OncoFAP-23,Inapplicable

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Isotopia

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth